Should you buy Repligen (RGEN)?
Updated
Repligen Corporation carries exceptional business quality with a perfect Piotroski F-Score of 9/9 and 134% free cash flow conversion, and analysts see 21% upside, but the stock trades at a forward P/E of 51.4x while sitting below its 200-day moving average with elevated bearish options positioning.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Engine methodology range
Range computation requires sufficient peer-comparable data; available for tickers with peer_count ≥3.
What the engine is tracking
| Pillar | Expectation | Trend |
|---|---|---|
Repligen earned a perfect Piotroski F-Score of 9/9 with 134% free cash flow conversion relative to net income and a confirmed competitive moat score of 7.1 out of 10, indicating a high-quality business model in medical instruments and bioprocessing supplies. Quality breakdown | Piotroski F-Score remains at 8 or above and free cash flow conversion stays above 100% of net income over the next 4 quarters. | →Stable |
| CounterDespite the strong quality indicators, return on equity and return on assets are both scored near the bottom of the quality dimension, suggesting the moat has not yet translated into superior capital returns. | ||
The company has beaten earnings estimates in 3 of the last 4 quarters with average positive surprises of 22.9%, 10.4%, and 10.9% in the three most recent beats, demonstrating consistent outperformance of consensus expectations. Earnings | Earnings beats continue in at least 3 of the next 4 quarters, with average surprise remaining above 5%. | →Stable |
| CounterThe one miss in July 2025 saw a -5% shortfall, and with a forward P/E of 51.4x, any earnings disappointment at this valuation level could produce outsized stock price declines. | ||
At a forward P/E of 51.4x and PEG of 2.06, the stock commands a significant growth premium, with analysts still seeing 21% upside to a price target of approximately $158, suggesting the premium is supported by expected growth acceleration. Valuation breakdown | The stock reaches at least $155 within 18 months as earnings growth justifies the valuation premium. | →Stable |
| CounterA PEG ratio above 2.0 combined with a stock trading below its 200-day moving average indicates that growth expectations may already be partially de-rated, with further valuation compression possible if growth disappoints. | ||
Repligen earned a perfect Piotroski F-Score of 9/9 with 134% free cash flow conversion relative to net income and a confirmed competitive moat score of 7.1 out of 10, indicating a high-quality business model in medical instruments and bioprocessing supplies.
→Stable- Expectation
- Piotroski F-Score remains at 8 or above and free cash flow conversion stays above 100% of net income over the next 4 quarters.
CounterDespite the strong quality indicators, return on equity and return on assets are both scored near the bottom of the quality dimension, suggesting the moat has not yet translated into superior capital returns.
The company has beaten earnings estimates in 3 of the last 4 quarters with average positive surprises of 22.9%, 10.4%, and 10.9% in the three most recent beats, demonstrating consistent outperformance of consensus expectations.
→Stable- Expectation
- Earnings beats continue in at least 3 of the next 4 quarters, with average surprise remaining above 5%.
CounterThe one miss in July 2025 saw a -5% shortfall, and with a forward P/E of 51.4x, any earnings disappointment at this valuation level could produce outsized stock price declines.
At a forward P/E of 51.4x and PEG of 2.06, the stock commands a significant growth premium, with analysts still seeing 21% upside to a price target of approximately $158, suggesting the premium is supported by expected growth acceleration.
→Stable- Expectation
- The stock reaches at least $155 within 18 months as earnings growth justifies the valuation premium.
CounterA PEG ratio above 2.0 combined with a stock trading below its 200-day moving average indicates that growth expectations may already be partially de-rated, with further valuation compression possible if growth disappoints.
▸ Show 1 more pillar▾ Show fewer
The elevated put/call ratio of 1.62 and implied volatility of 84% indicate meaningful bearish hedging activity in the options market, which combined with 11% short interest suggests significant skepticism about near-term price appreciation.
→Stable- Expectation
- Put/call ratio declines below 1.0 and short interest falls below 7% over the next 12 months as the earnings recovery thesis proves out.
CounterElevated put/call ratios can be contrarian signals when institutional hedgers are protecting existing long positions rather than expressing directional bearish views, especially when underlying business quality is high.
→ Full pillar scorecard with all 4 pillars + per-dimension breakdown
When this thesis breaks
Falsifiable conditions per pillar — any one trip warrants review independent of price action. Engine-derived; not personalized advice.
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Repligen earned a perfect Piotroski F-Score of 9/9 with 134% free cash flow conversion relative to net income and a confirmed competitive moat score of 7.1 out of 10, indicating a high-quality business model in medical instruments and bioprocessing supplies.
Trip ifPiotroski F-Score drops below 7 in any reported period or free cash flow conversion falls below 80% of net income.
- P2The company has beaten earnings estimates in 3 of the last 4 quarters with average positive surprises of 22.9%, 10.4%, and 10.9% in the three most recent beats, demonstrating consistent outperformance of consensus expectations.
Trip ifEarnings surprise falls below -5% in at least 2 of the next 4 quarters.
- P3At a forward P/E of 51.4x and PEG of 2.06, the stock commands a significant growth premium, with analysts still seeing 21% upside to a price target of approximately $158, suggesting the premium is supported by expected growth acceleration.
Trip ifStock fails to reach above $155 within 18 months from today's price of $130.87.
- P4The elevated put/call ratio of 1.62 and implied volatility of 84% indicate meaningful bearish hedging activity in the options market, which combined with 11% short interest suggests significant skepticism about near-term price appreciation.
Trip ifPut/call ratio rises above 2.0 or short interest rises above 15%.
How the engine reached this verdict
TrendMatrix's engine output for Repligen Corporation (RGEN) is SELL_IF_HOLDING with medium conviction, score 5.2/10 at $146.35. The F-path SELL output reflects an overall score of 5.2 below the 5.6 soft trigger — multiple weakening dimensions accumulated rather than a single hard-floor breach. Asymmetry R:R of 0.56 is supplementary context, not the trigger.
The engine's exit framework anchors to a tactical sell band near $146.35, with structural invalidation at $135.99. The asymmetric R:R against a reversal hypothesis is 1.20 — the upside scenario exists, but it requires multiple structural gates to flip; the downside scenario requires only one more disappointment. The engine's sizing output: 0.5% of portfolio at this asymmetry level (none-conviction tier).
On the bull side: Strong earnings beat streak (3/4); Strong growth profile. On the bear side: Concentration risk — Supplier: single-source supplier (certain products); Thin upside margin: 8.4%; Expensive valuation. Active engine warnings: V9 Gate Failed: ASYMMETRY:0.6<1.5@spot.
The dominant failed gate is reward-to-risk at 0.6 vs threshold 1.5. SELL flips back toward HOLD if reward-to-risk recovers above its threshold AND a co-failing gate also clears. The strongest-cleared gate today is MOMENTUM:6.8>=5.5.
For the full 10-dimension breakdown + V9 gate detail: Why TrendMatrix rates RGEN — 10-dimension breakdown →
Bull case
- ▸Strong earnings beat streak (3/4)
- ▸Strong growth profile
Bear case
- ▸Concentration risk — Supplier: single-source supplier (certain products)
- ▸Thin upside margin: 8.4%
- ▸Expensive valuation